2023
High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
Galvez S, Altice F, Meteliuk A, Ivasiy R, Machavariani E, Farnum S, Fomenko T, Islam Z, Madden L. High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine. Frontiers In Public Health 2023, 11: 1231581. PMID: 38098837, PMCID: PMC10720365, DOI: 10.3389/fpubh.2023.1231581.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderAgonist therapyOAT patientsCOVID-19 pandemicSubstance useTake-home dosingAdditional psychosocial supportHigher perceived stressHigh riskPerceived Stress ScalePsychiatric disordersUse disordersPatientsPatient stressPsychosocial supportCertain subgroupsSevere levelsHigh levelsHealthcare deliveryStress ScalePerceived stressTherapyExtraordinary high levelsDisordersPreferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis
Muthulingam D, Hassett T, Madden L, Bromberg D, Fraenkel L, Altice F. Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis. Journal Of Substance Use And Addiction Treatment 2023, 154: 209138. PMID: 37544510, DOI: 10.1016/j.josat.2023.209138.Peer-Reviewed Original ResearchConceptsOpioid use disorderRoute of administrationPatient preferencesUse disordersSymptom reliefTreatment preferencesSide effectsCross-sectional observational studyTreatment-seeking peopleChi-squared analysisOral medicationsPublic health crisisOUD treatmentTreatment uptakeWithdrawal symptomsOpioid epidemicObservational studyTreatment decisionsSTROBE checklistSustainability of treatmentPatientsMedicationsHealth professionalsUtility scoresLarger studyImproving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches
Brooks R, Wegener M, Freeman B, Fowles C, Madden L, Tetrault J, Nichols L, Altice F, Villanueva M. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. Health Promotion Practice 2023, 24: 1018-1028. PMID: 37439759, DOI: 10.1177/15248399231169791.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionSubstance use disorder programsHCV testingOpiate use disorderHCV coinfectionUse disordersNominal group techniqueSubstance use disorder treatment centersCascade of careRates of HIVDisorder treatment centersQuality improvement effortsRate of testingHCV acquisitionHCV cureImproving HIVSUD clinicsHepatitis CHIV testingPrior diagnosisSubsequent referralReferral ratesHIV epidemicHIVTreatment centersLeveraging existing provider networks in Europe to eliminate barriers to accessing opioid agonist maintenance therapies for Ukrainian refugees
Nikitin B, Bromberg D, Madden L, Stöver H, Teltzrow R, Altice F. Leveraging existing provider networks in Europe to eliminate barriers to accessing opioid agonist maintenance therapies for Ukrainian refugees. PLOS Global Public Health 2023, 3: e0002168. PMID: 37440470, PMCID: PMC10343058, DOI: 10.1371/journal.pgph.0002168.Peer-Reviewed Original ResearchOpioid use disorderAgonist maintenance therapyMaintenance therapyInjection drug usePrevention of HIVGold standard treatmentRisk of HIVHigh prevalence ratesCare continuityStandard treatmentPrevalence ratesUse disordersImplementation science lensDrug useHarm reductionTreatment modelHIVPatientsClinicTherapyAddiction treatment modelsTreatmentProvidersInvasionInterview participantsCorrelates of Perceived Discrimination Related to Substance Use Disorders Among Patients in Methadone Maintenance Treatment
Nwanaji-Enwerem U, Beitel M, Oberleitner D, Gazzola M, Eggert K, Oberleitner L, Jegede O, Zheng X, Redeker N, Madden L, Barry D. Correlates of Perceived Discrimination Related to Substance Use Disorders Among Patients in Methadone Maintenance Treatment. Journal Of Psychoactive Drugs 2023, 56: 530-540. PMID: 37399330, PMCID: PMC10761588, DOI: 10.1080/02791072.2023.2230571.Peer-Reviewed Original ResearchMethadone maintenance treatmentSubstance use disordersLogistic regression modelsUse disordersMaintenance treatmentTreatment-related characteristicsOpioid use disorderFinal logistic regression modelBSI-18 depressionAge of onsetRegression modelsMMT programDepressive symptomsMeasures of demographicsPatientsBivariate analysisSubstance abuseSignificant correlatesDisordersCorrelatesMedian splitAgeParticipantsTreatmentLikert-type scaleApplication of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study
Mistler C, Shrestha R, Gunstad J, Collins L, Madden L, Huedo-Medina T, Sibilio B, Copenhaver N, Copenhaver M. Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study. BMJ Open 2023, 13: e071688. PMID: 37399447, PMCID: PMC10314648, DOI: 10.1136/bmjopen-2023-071688.Peer-Reviewed Original ResearchConceptsOpioid use disorderMultiphase optimization strategyCognitive dysfunctionHIV preventionUse disordersPromising biomedical interventionsPre-exposure prophylaxisHIV incidence ratesHIV risk reductionHIV prevention interventionsDrug treatment settingsInstitutional review boardInformed consent formPrEP adherenceHIV prevention contentHIV infectionPrEP uptakeStudy protocolIncidence rateRisk groupsPrevention interventionsPWIDTreatment settingsReview boardEffective interventions“Just fighting for my life to stay alive”: a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories
Hoffman K, Thompson E, Gaeta Gazzola M, Oberleitner L, Eller A, Madden L, Marcus R, Oberleitner D, Beitel M, Barry D. “Just fighting for my life to stay alive”: a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories. Addiction Science & Clinical Practice 2023, 18: 16. PMID: 36944998, PMCID: PMC10031976, DOI: 10.1186/s13722-023-00377-y.Peer-Reviewed Original ResearchConceptsOpioid use disorderRe-entry experiencesReintegration of peopleSemi-structured qualitative interviewsIncarceration historyExperiences of peoplePerspectives of peopleBasic resourcesThematic analysis approachTransition programCarceral settingsQualitative interviewsLived experienceStable housingStructural barriersSocial challengesFormal transition programQualitative investigationPersistent barriersIncarcerationHistory of incarcerationUse disordersConcrete suggestionsMain themesRe-entry periodA National Study of Homelessness, Social Determinants of Health, and Treatment Engagement Among Outpatient Medication for Opioid Use Disorder-Seeking Individuals in the United States
Gazzola M, Carmichael I, Christian N, Zheng X, Madden L, Barry D. A National Study of Homelessness, Social Determinants of Health, and Treatment Engagement Among Outpatient Medication for Opioid Use Disorder-Seeking Individuals in the United States. Substance Use & Addiction Journal 2023, 44: 62-72. PMID: 37226909, DOI: 10.1177/08897077231167291.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersClinical characteristicsTreatment completionTreatment engagementTreatment Episodes Dataset-DischargesSocial determinantsLogistic regression modelsImportant social determinantOutpatient medicationsTreatment discontinuationIndependent predictorsCare treatmentTreatment episodesTreatment enrollmentMedical conditionsSDoH variablesHealth outcomesTreatment lengthGreater social vulnerabilityTreatment entryMOUDVulnerable populationsPoor engagementMedications
2022
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriersEnhancing Use of Medications for Opioid Use Disorder Through External Coaching
Molfenter T, Kim H, Kim JS, Kisicki A, Knudsen HK, Horst J, Brown R, Madden LM, Toy A, Haram E, Jacobson N. Enhancing Use of Medications for Opioid Use Disorder Through External Coaching. Psychiatric Services 2022, 74: 265-271. PMID: 36196533, PMCID: PMC10836327, DOI: 10.1176/appi.ps.202100675.Peer-Reviewed Original ResearchConceptsOpioid use disorderBuprenorphine useControl armUse disordersUse of MOUDUse of medicationsInjectable naltrexoneNaltrexone administrationOutcome measuresCoaching armClinical sitesHealth systemProvider UtilizationTrial periodTreatment agenciesTrialsDelivery modalitiesHealth sitesMedicationsSignificant differencesDisordersArmSimilar patternMOUDNaltrexoneWhat’s in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment
Gazzola MG, Maclean E, Beitel M, Carmichael ID, Cammack KM, Eggert KF, Roehrich T, Madden LM, Jegede O, Zheng X, Bergman E, Barry DT. What’s in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment. Journal Of General Internal Medicine 2022, 38: 653-660. PMID: 36163526, PMCID: PMC9971370, DOI: 10.1007/s11606-022-07813-w.Peer-Reviewed Original ResearchConceptsOpioid use disorderSubstance use disordersMethadone treatmentUse disordersOutpatient methadone treatment programMethadone treatment programsPresenting problemPreferences of patientsTerminology preferencesSubstance-dependent personsCross-sectional surveyAdult patientsMean ageUnivariate analysisMain MeasuresParticipantsPatientsTreatment programKey ResultsWeSubstance abuseSubstance useDisordersSignificant differencesTreatmentDemographic differencesAddiction counselorsA Student Walks into Class … Vignettes to Identify Substance Use Disorder Models of Illness among College Students
Barry DT, Oberleitner DE, Beitel M, Oberleitner LMS, Gazzola MG, Eller A, Madden LM, Zheng X, Bergman E, Tamberelli JF. A Student Walks into Class … Vignettes to Identify Substance Use Disorder Models of Illness among College Students. Substance Use & Misuse 2022, 57: 1523-1533. PMID: 35787230, DOI: 10.1080/10826084.2022.2091787.Peer-Reviewed Original ResearchConceptsSubstance use disordersChronic medical conditionsIllness recognitionModels of illnessSubstance useMedical conditionsIllness modelDSM-5 substance use disordersTreatment-seeking behaviorDSM-5 diagnostic criteriaDiagnostic criteriaUse disordersIllnessHeroinGroup differencesCannabisSeverityVicodinMore participantsCocaineDisordersParticipantsAddictionTobaccoPsychoeducationStrengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection
Eller AJ, DiDomizio EE, Madden LM, Oliva JD, Altice FL, Johnson KA. Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection. Annals Of Medicine 2022, 54: 1714-1724. PMID: 35775786, PMCID: PMC9377256, DOI: 10.1080/07853890.2022.2084154.Peer-Reviewed Original ResearchConceptsCascade of careHuman immunodeficiency virusOpioid use disorderHepatitis C virusPublic health planningUse disordersCo-occurring opioid use disorderHealth planningBurden of diseaseSystems of careQuality improvement activitiesOUD cascadeTreatment initiationImmunodeficiency virusC virusPatient outcomesTreatment accessPayer sourceTreatment retentionHealth systemHealthcare systemCareSyndemicDisordersVirusPregnant Women and Opioid Use Disorder: Examining the Legal Landscape for Controlling Women's Reproductive Health.
Madden L, Oliva J, Eller A, DiDomizio E, Roosa M, Blanchard L, Kil N, Altice F, Johnson K. Pregnant Women and Opioid Use Disorder: Examining the Legal Landscape for Controlling Women's Reproductive Health. American Journal Of Law & Medicine 2022, 48: 209-222. PMID: 36715261, DOI: 10.1017/amj.2022.26.Peer-Reviewed Original ResearchConceptsOpioid use disorderReproductive healthPregnant womenUse disordersPregnant women's useEvidence-based treatmentsReproductive health outcomesWomen's reproductive healthIntersection of HIVSystems of careHealth care choicesPostpartum womenChild healthTreatment policyUnintentional pregnancyHealth outcomesLarger studyWomenTransactional sexCare choicesMinority womenOutcomesOUDWomen's useDisordersPrimary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting
Haque LY, Butner JL, Shi JM, Henry S, Deng Y, Ciarleglio MM, Madden LM, Tetrault JM. Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting. Journal Of Addiction Medicine 2022, 16: 333-339. PMID: 34483278, PMCID: PMC9033626, DOI: 10.1097/adm.0000000000000910.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionUrine toxicology resultsDirect acting antiviralsViral load testingSubstance use disordersAddiction treatment programsHCV reinfectionActing antiviralsToxicology resultsUse disordersDirect acting antiviral therapyTreatment programReal-world clinical settingHCV reinfection ratesActing antiviral (DAA) therapyC virus infectionHepatitis C infectionMedical service useCohort of patientsPrimary medical careSubstance use statusAddiction treatment settingsQuality improvement initiativesHCV cureC infectionCharacterizing the social support and functioning of a low-threshold medication for opioid use disorder treatment cohort at intake
Oles W, Alexander M, Kumar N, Howell B, O’Connor P, Madden LM, Barry DT. Characterizing the social support and functioning of a low-threshold medication for opioid use disorder treatment cohort at intake. BMC Psychiatry 2022, 22: 236. PMID: 35366844, PMCID: PMC8976510, DOI: 10.1186/s12888-022-03884-5.Peer-Reviewed Original ResearchConceptsLow-threshold clinicDemographic characteristicsOpioid use disorder treatmentMultivariate logistic regression modelBrief Pain InventoryPatient demographic characteristicsOpioid use disorderSocial supportSymptom Identification ScaleUse disorder treatmentNon-Hispanic whitesLogistic regression modelsOlder patientsPain InventoryTreatment cohortsSelf-reported social supportLife Events ChecklistMOUD treatmentBaseline disparitiesTreatment accessTreatment needsHigh riskUse disordersMortality rateDisorder treatmentThe development and initial validation of the Russian version of the BASIS-24
Madden L, Farnum S, Bromberg D, Barry D, Mazhnaya A, Fomenko T, Meteliuk A, Marcus R, Rozanova J, Poklad I, Dvoriak S, Altice F. The development and initial validation of the Russian version of the BASIS-24. Addiction Science & Clinical Practice 2022, 17: 65. PMID: 36435811, PMCID: PMC9701377, DOI: 10.1186/s13722-022-00343-0.Peer-Reviewed Original ResearchConceptsBASIS-24Addiction treatmentHIV prevention goalsSubset of patientsOpioid use disorderSymptom Identification ScaleMental health statusResultsCronbach’s alpha coefficientsMOUD patientsSeverity InstrumentTuberculosis epidemicEffective treatmentUse disordersHealth statusHealthcare professionalsMental healthPrevention goalsRelationships subscaleTreatment deliveryExploratory principal component analysisOpioidsHIVPatientsAlpha coefficientEECA region
2021
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients
Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal Of Drug Policy 2021, 101: 103570. PMID: 34954493, PMCID: PMC8685180, DOI: 10.1016/j.drugpo.2021.103570.Peer-Reviewed Original ResearchConceptsOpioid use disorderHepatitis C virusSyringe services programDifferentiated care modelPerson visitsC virusCare modelUse disordersInitiation of DAAChronic HCV infectionEvidence-based treatmentsCOVID-19Initial phlebotomyVirological responseHCV infectionHCV treatmentAdditional patientsElevated riskPatientsClient-centred approachPWIDHIVPerson contactTreatment demandLaboratory screeningPrescribers’ satisfaction with delivering medications for opioid use disorder
Knudsen HK, Brown R, Jacobson N, Horst J, Kim JS, Kim H, Madden LM, Haram E, Molfenter T. Prescribers’ satisfaction with delivering medications for opioid use disorder. Substance Abuse Treatment, Prevention, And Policy 2021, 16: 78. PMID: 34663379, PMCID: PMC8521499, DOI: 10.1186/s13011-021-00413-7.Peer-Reviewed Original ResearchConceptsType of MOUDOpioid use disorderPrescriber satisfactionPrescriber characteristicsUse disordersXR-naltrexoneBuprenorphine treatmentExtended-release naltrexoneUS opioid epidemicOverall satisfactionRelease naltrexoneGreater overall satisfactionClinical trialsOpioid epidemicMethodsAs partMOUDWeb-based surveyPatient censusPrescribersMedicationsBuprenorphineDisordersTreatmentCurrent studyHigh levelsPreference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders
Meyer J, Price C, Tracey D, Sharpless L, Song Y, Madden L, Elwyn G, Altice F. Preference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders. Patient Preference And Adherence 2021, 15: 1913-1927. PMID: 34511887, PMCID: PMC8420782, DOI: 10.2147/ppa.s315543.Peer-Reviewed Original ResearchSubstance use disordersPersonal HIV riskHIV preventionAddiction treatment servicesHIV riskUse disordersTreatment servicesPatient-centered decision aidAwareness of PrEPHIV prevention cascadeInitiation of PrEPPre-exposure prophylaxisOpioid use disorderStandard of careDecision aidAlcohol use severityHalf of participantsAddiction treatment programsDA participantsPrevention cascadePrimary outcomeIndependent correlatesHigh riskDecisional preferencesHigher alcohol use severity